Washington, D.C.: US President Donald Trump has unveiled a phased tariff plan targeting imported generic medicines, a move that could have significant implications for global pharmaceutical trade, particularly for India, the largest supplier of generic drugs to the United States.
In a statement shared on his social media platform, Truth Social, Trump said imported generic medicines would continue to enter the US without tariffs for the next two years. However, beginning in August 2028, the tariff structure will change sharply, with imported generic drugs facing a 100 per cent duty for one year, followed by a 200 per cent tariff thereafter.
According to Trump, the policy is intended to encourage pharmaceutical manufacturers to shift production to the United States and reduce the country’s dependence on overseas suppliers for essential medicines.
The announcement comes as part of the administration’s broader push to strengthen domestic manufacturing across strategic sectors, including pharmaceuticals. Trump has repeatedly argued that increasing local production would improve supply chain resilience and create more jobs within the US.
The proposed tariff regime is expected to have major ramifications for India’s pharmaceutical industry, which accounts for a substantial share of generic medicines sold in the American market. Indian drug manufacturers have long relied on exports to the US, making it one of their largest overseas markets.
Industry observers believe the proposed duties, if implemented as announced, could increase the cost of generic medicines in the US while forcing exporters to reassess their production and pricing strategies. Companies may also explore expanding manufacturing facilities within the United States to maintain market access.
While the announcement outlines the administration’s intended timeline, stakeholders are expected to closely monitor further policy details and implementation guidelines in the coming months. The proposal is likely to trigger discussions between industry representatives, healthcare experts and trade partners over its potential impact on medicine affordability, supply chains and international trade.
